Senseonics Holdings Inc (NASDAQ:SENS) has earned an average broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company. Senseonics Holdings’ rating score has declined by 12.8% in the last three months as a result of various analysts’ ratings changes.

Brokerages have set a one year consensus price objective of $4.75 for the company and are anticipating that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also given Senseonics Holdings an industry rank of 159 out of 265 based on the ratings given to related companies.

Several equities analysts have commented on the stock. Zacks Investment Research cut shares of Senseonics Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. BTIG Research reissued a “buy” rating and issued a $4.50 price target on shares of Senseonics Holdings in a research report on Sunday, May 28th.

ILLEGAL ACTIVITY WARNING: “Zacks: Senseonics Holdings Inc (SENS) Given $4.75 Average Price Target by Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/16/zacks-senseonics-holdings-inc-sens-given-4-75-average-price-target-by-analysts.html.

Shares of Senseonics Holdings (NASDAQ:SENS) traded up 2.57% during trading on Friday, reaching $3.19. 658,049 shares of the company were exchanged. Senseonics Holdings has a 1-year low of $2.15 and a 1-year high of $4.05. The stock’s market capitalization is $393.01 million. The firm has a 50-day moving average price of $3.09 and a 200-day moving average price of $2.74.

Senseonics Holdings (NASDAQ:SENS) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.01. The business had revenue of $0.81 million during the quarter, compared to analysts’ expectations of $0.81 million. Equities research analysts predict that Senseonics Holdings will post ($0.54) earnings per share for the current fiscal year.

In other news, COO Mukul Jain sold 13,115 shares of Senseonics Holdings stock in a transaction on Monday, September 11th. The shares were sold at an average price of $3.25, for a total transaction of $42,623.75. Following the completion of the sale, the chief operating officer now directly owns 13,115 shares of the company’s stock, valued at approximately $42,623.75. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Several institutional investors have recently added to or reduced their stakes in SENS. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Senseonics Holdings during the 1st quarter worth $147,000. Renaissance Technologies LLC purchased a new stake in shares of Senseonics Holdings during the 1st quarter worth $111,000. HarbourVest Partners LLC purchased a new stake in shares of Senseonics Holdings during the 1st quarter worth $470,000. Blackstone Group L.P. purchased a new stake in shares of Senseonics Holdings during the 1st quarter worth $614,000. Finally, ING Groep NV lifted its position in shares of Senseonics Holdings by 87.7% during the 2nd quarter. ING Groep NV now owns 225,833 shares of the company’s stock worth $406,000 after purchasing an additional 105,494 shares during the last quarter.

Senseonics Holdings Company Profile

Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.

Get a free copy of the Zacks research report on Senseonics Holdings (SENS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Senseonics Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.